| Followers | 200 |
| Posts | 25597 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Sunday, April 02, 2017 8:57:33 AM
It may be settled to resolve it, but if it were taken to trial, I doubt Yonemura would be resolved in favor of the plaintiff. The Business Judgment rule and a whole slew of other reasons would make that case very unlikely to be resolved in the plaintiff's favor, and without the other case, which alleged all sorts of conflicts of interest and collusion, which appears to not have been proven, I think Yonemura would have failed, right out of the gate.
They are not entirely disconnected, because one case provides the justification for the other being made, in truth, if not by admission. Fundamentally, the allegations of the other case, of bad actions, conflicts of interest, etc., are also the justification for the same allegations in Yonemura. But it will resolve differently because they do not technically base their claims upon one another and the Yonemura complaint, in my opinion, is more carefully and tightly drafted. That they are resolving it, if it's a reasonable resolution, is a good thing.
They are not entirely disconnected, because one case provides the justification for the other being made, in truth, if not by admission. Fundamentally, the allegations of the other case, of bad actions, conflicts of interest, etc., are also the justification for the same allegations in Yonemura. But it will resolve differently because they do not technically base their claims upon one another and the Yonemura complaint, in my opinion, is more carefully and tightly drafted. That they are resolving it, if it's a reasonable resolution, is a good thing.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
